Clinical trial updates and time-limited therapy in CLL

Epsidoe 35 - 2024 Highlights and Hindsight in CLL End of Year UpdatesПодробнее

New Research on Time-Limited Therapies for Chronic Lymphocytic Leukemia with Dr. Farrukh Awan, M.D.Подробнее

2024 Highlights and Hindsight in CLL: End of Year UpdatesПодробнее

Time-Limited Ibrutinib Plus Venetoclax for CLL - Dr. Nitin Jain ASH 2023Подробнее

Optimizing initial therapy in CLL: time-limited, all-oral approachesПодробнее

Continuous Vs time - limited therapy for CLL with recent updatesПодробнее

Exploring Newer Time-Limited BTKi Combinations in CLLПодробнее

Continuous BTKi therapy in CLL: are time-limited combination therapies more beneficial?Подробнее

2024 Highlights and Hindsight in CLL End of Year UpdatesПодробнее

Chronic Lymphocytic Leukemia | Key Presentations on CLL from Recent Major ConferencesПодробнее

Selection for time-limited & continuous therapy in CLLПодробнее

Time-limited vs continuous therapy in CLL treatmentПодробнее

Moving towards time-limited treatment in frontline CLLПодробнее

GAIA/CLL13: Venetoclax-based time-limited combination therapies in CLLПодробнее

Defying the Odds With Innovation in CLLПодробнее

HOVON 141/VISION: MRD guided time-limited treatment in CLLПодробнее

Time-limited for CLL and lymphoma – who, what, and how?Подробнее

An insight into time-limited therapy in CLLПодробнее

How do you decide between continuous or time-limited therapy for CLL?Подробнее